166 related articles for article (PubMed ID: 16445639)
1. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies.
Melichar B; Solichová D; Freedman RS
Int J Gynecol Cancer; 2006; 16(1):240-52. PubMed ID: 16445639
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
[TBL] [Abstract][Full Text] [Related]
3. Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?
Andersen CL; Eskelund CW; Siersma VD; Felding P; Lind B; Palmblad J; Bjerrum OW; Friis S; Hasselbalch HC; de Fine Olivarius N
Gynecol Oncol; 2015 Nov; 139(2):312-8. PubMed ID: 26407478
[No Abstract] [Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
5. Relationship between epidermal growth factor receptor and other prognostic factors in gynecological cancers.
Melpignano M; Vadora E; Debiasi D; Merisio C; Piombo S; Brusati M; Catozzi L; Giovannini G; Piffanelli A; Merialdi A
Acta Biomed Ateneo Parmense; 1993; 64(5-6):227-34. PubMed ID: 7992560
[TBL] [Abstract][Full Text] [Related]
6. Preactivated T cells in cancer patients with poor prognosis.
Fuchs DN; Fuith LC; Hausen A; Hetzel H; Reibnegger GJ; Werner ER; Wachter H
Cancer Detect Prev; 1988; 12(1-6):97-103. PubMed ID: 3141055
[TBL] [Abstract][Full Text] [Related]
7. [Grading of gynecological tumors : Current aspects].
Horn LC; Mayr D; Brambs CE; Einenkel J; Sändig I; Schierle K
Pathologe; 2016 Jul; 37(4):337-51. PubMed ID: 27379622
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
9. Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).
Volgger BM; Windbichler GH; Zeimet AG; Graf AH; Bogner G; Angleitner-Boubenizek L; Rohde M; Denison U; Sliutz G; Fuith LC; Fuchs D; Marth C
Ann Oncol; 2016 Sep; 27(9):1740-6. PubMed ID: 27358381
[TBL] [Abstract][Full Text] [Related]
10. [Gynecological cancers and pregnancy: the point of view of the oncology gynecologist].
Morice P; Camatte S; Pautier P; Castaigne V; Germann N; Pomel C; Haie-Meder C; Lhommé C; Duvillard P; Dargent D; Castaigne D
Bull Cancer; 2002 Sep; 89(9):765-71. PubMed ID: 12368128
[TBL] [Abstract][Full Text] [Related]
11. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries.
Melichar B; Tousková M; Tosner J; Kopecký O
Onkologie; 2001 Apr; 24(2):156-60. PubMed ID: 11441296
[TBL] [Abstract][Full Text] [Related]
12. A New Diagnostic and Prognostic Marker in Endometrial Cancer: Neopterin.
Isci Bostanci E; Ugras Dikmen A; Girgin G; Gungor T; Baydar T; Nuri Danisman A
Int J Gynecol Cancer; 2017 May; 27(4):754-758. PubMed ID: 28383326
[TBL] [Abstract][Full Text] [Related]
13. Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.
Zeimet AG; Reimer D; Schwentner L; Fuchs D; Wolf D; Fuith LC; Fiegl H; Doppler W; Concin N; Daxenbichler G; Marth C
Cancer Immunol Immunother; 2010 Dec; 59(12):1813-23. PubMed ID: 20717669
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan degradation in patients with gynecological cancer correlates with immune activation.
Schroecksnadel K; Winkler C; Fuith LC; Fuchs D
Cancer Lett; 2005 Jun; 223(2):323-9. PubMed ID: 15896467
[TBL] [Abstract][Full Text] [Related]
15. Synchronous primary malignancies of the female genital tract.
Ayhan A; Yalçin OT; Tuncer ZS; Gürgan T; Küçükali T
Eur J Obstet Gynecol Reprod Biol; 1992 Jun; 45(1):63-6. PubMed ID: 1618363
[TBL] [Abstract][Full Text] [Related]
16. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
Vaidya AP; Parnes AD; Seiden MV
Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
[TBL] [Abstract][Full Text] [Related]
17. Measurement of urinary neopterin in normal pregnant and non-pregnant women and in women with benign and malignant genital tract neoplasms.
Bichler A; Fuchs D; Hausen A; Hetzel H; Reibnegger G; Wachter H
Arch Gynecol; 1983; 233(2):121-30. PubMed ID: 6882017
[TBL] [Abstract][Full Text] [Related]
18. Neopterin, a prognostic marker in human malignancies.
Sucher R; Schroecksnadel K; Weiss G; Margreiter R; Fuchs D; Brandacher G
Cancer Lett; 2010 Jan; 287(1):13-22. PubMed ID: 19500901
[TBL] [Abstract][Full Text] [Related]
19. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8.
Neurauter G; Grahmann AV; Klieber M; Zeimet A; Ledochowski M; Sperner-Unterweger B; Fuchs D
Cancer Lett; 2008 Dec; 272(1):141-7. PubMed ID: 18701209
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 serum levels in patients with gynecological tumors.
Scambia G; Testa U; Panici PB; Martucci R; Foti E; Petrini M; Amoroso M; Masciullo V; Peschle C; Mancuso S
Int J Cancer; 1994 May; 57(3):318-23. PubMed ID: 8168990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
